LAVA-1207

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameLAVA-1207
Drug Alias NameLAVA-1207
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-PSMA +[4] 
TargetsProstate-Specific Membrane AntigenT cell receptor delta variable 2
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsGermany +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVu University Medical CenterLava Therapeutics NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLava Therapeutics NV
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms, Castration-Resistant

Other Information

ATC CodeN/A
Related LinksN/A